Identification of a 20-Gene Expression-Based Risk Score as a Predictor of Clinical Outcome in Chronic Lymphocytic Leukemia Patients
Figure 2
Prognostic value of GE-based risk score in CLL patients. (a) Patients of the training cohort () were ranked according to increasing GE-based risk score and a maximum difference in OS was obtained with a score , splitting patients into a high risk (19,6%) and a low risk (80,4%) groups. (b) The prognostic value of GE-based risk score was assayed on an independent cohort of 44 patients (validation cohort). The parameters to compute GE-based risk score of patients in the validation cohort and the proportions delineating the 2 prognostic groups were those defined with the training cohort.
